SELECT-D Collaborative Group (Including: Young, Annie M., Marshall, Andrea, Thirlwall, Jenny, Chapman, Oliver, Lokare, Anand, Hill, Catherine, Hale, Danielle, Dunn, Janet A., Lyman, Gary H., Hutchinson, Charles, MacCallum, Peter, Kakkar, Ajay, Hobbs, F. D. Richard, Petrou, Stavros, Dale, Jeremy, Poole, Christopher J., Maraveyas, Anthony and Levine, Mark). (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism : results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36 (20). pp. 2017-2023. doi:10.1200/JCO.2018.78.8034

Preview	PDF WRAP-SELECT-D-comparison-oral-factor-Xa-inbibitor-low-cancer-venous-randomized-Petrou-2018.pdf - Published Version - Requires a PDF viewer. Download (1924Kb) | Preview
	PDF WRAP-comparison-oral-factor-Xa-inhibitor-low-molecular-weight-Petrou-2018.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (498Kb)

Request Changes to record.

Abstract

Purpose:

Venous thromboembolism (VTE) is common in cancer patients. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral Factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in cancer patients. Patient and

Methods:

In this UK multicentre, randomised, open-label, pilot trial, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE or symptomatic lower extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily, month 1, then 150 IU/kg, months 2-6) or rivaroxaban (15 mg twice daily for three weeks, then 20 mg once daily) for six months. The primary outcome was VTE recurrence over six months. Safety was assessed by major bleeding and clinically relevant non-major bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within +/ 4.5% assuming a VTE recurrence rate at six months of 10%.

Results:

Two hundred and three patients were randomised to each group; 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (18 dalteparin, 8 rivaroxaban). The six month cumulative VTE recurrence rate with dalteparin was 11% (95% CI 7-16%) and 4% (95% CI 2-9%) with rivaroxaban, hazard ratio (HR) 0.43, (95% CI 0.19-0.99). The six month cumulative rate of major bleeding was 4% (95% CI 2-8%) for dalteparin and 6% (95% CI 3-11%) for rivaroxaban, HR 1.83, (95% CI 0.68-4.96). Corresponding rates of CRNMB were 4% (95% CI 2-9%) and 13% (95% CI 9-19%) respectively, HR 3.76, (95% CI 1.63-8.69).

Conclusion:

Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared to dalteparin.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Thrombophlebitis -- Treatment, Cancer -- Complications
Journal or Publication Title:	Journal of Clinical Oncology
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Official Date:	July 2018
Dates:	Date Event July 2018 Published 10 May 2018 Available 3 April 2018 Accepted
Volume:	36
Number:	20
Page Range:	pp. 2017-2023
DOI:	10.1200/JCO.2018.78.8034
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
RIOXX Funder/Project Grant:	Project/Grant ID RIOXX Funder Name Funder ID UNSPECIFIED Bayer AG http://viaf.org/viaf/134841299
Related URLs:	Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item